Tue, 26 Jan 2010 13:09:01 -0500 PVI, PeerView Institute for Medical Education http://www.peerviewpress.com Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker Thought leader perspectives on current clinical advances in medicine PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2007 PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://media.peerviewpress.com/000136/podcast/pvi/xml/podcast_oncologyCME-CNE-CPE_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Oncology no PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE05844r77.mp3 Tue, 26 Jan 2010 12:58:24 -0500 Science, Medicine no 00:26:18 follicular lymphoma, NHL, rituximab, CHOP, relapsed, refractory, bendamustine, autologous, allogeneic, HSCT, CD20 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05844CMEinfo.pdf Tue, 26 Jan 2010 12:58:15 -0500 Science, Medicine no 00:00:00 follicular lymphoma, NHL, rituximab, CHOP, relapsed, refractory, bendamustine, autologous, allogeneic, HSCT, CD20 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE06139e29.mp3 Fri, 18 Dec 2009 14:45:22 -0500 Science, Medicine no 00:22:17 difficult-to-treat, advanced breast cancer, triple negative, PARP inhibitors, epothilones, antiangiogenics, microtubule-targeting agents, chemotherapy-refractory PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06139CMEinfo.pdf Fri, 18 Dec 2009 14:45:19 -0500 Science, Medicine no 00:00:00 difficult-to-treat, advanced breast cancer, triple negative, PARP inhibitors, epothilones, antiangiogenics, microtubule-targeting agents, chemotherapy-refractory PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE06176r68.mp3 Thu, 17 Dec 2009 15:40:46 -0500 Science, Medicine no 00:35:19 Re-Evaluating Therapeutic Options for the Prevention and Management of CINV PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06176CMEinfo.pdf Thu, 17 Dec 2009 15:40:43 -0500 Science, Medicine no 00:00:00 Re-Evaluating Therapeutic Options for the Prevention and Management of CINV PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/mp3/Audio_Podcast_Audio_PPVNE06250.mp3 Thu, 10 Dec 2009 10:43:46 -0500 Science, Medicine no 00:30:16 NSCLC, lung cancer, maintenance, pemetrexed, cetuximab, erlotinib, targeted, cytotoxic, JMEN, treatment break PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06250CMEinfo.pdf Thu, 10 Dec 2009 10:43:24 -0500 Science, Medicine no 00:00:00 NSCLC, lung cancer, maintenance, pemetrexed, cetuximab, erlotinib, targeted, cytotoxic, JMEN, treatment break PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE05919r79.mp3 Thu, 19 Nov 2009 13:59:52 -0500 Science, Medicine no 00:14:17 CRC, colorectal cancer, bevacizumab, cetuximab, panitumumab, EGFR, oxaliplatin, FOLFOX, FOLFIRI, irinotecan PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05919CMEinfo.pdf Thu, 19 Nov 2009 13:59:46 -0500 Science, Medicine no 00:00:00 CRC, colorectal cancer, bevacizumab, cetuximab, panitumumab, EGFR, oxaliplatin, FOLFOX, FOLFIRI, irinotecan PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE06218hcc.mp3 Thu, 12 Nov 2009 14:39:24 -0500 Science, Medicine no 01:31:36 hepatocellular carcinoma, HCC, liver cancer, imaging tools, biomarkers, TACE, targeted therapy, multidisciplinary management PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE06218CMEinfo.pdf Thu, 12 Nov 2009 14:39:19 -0500 Science, Medicine no 00:00:00 hepatocellular carcinoma, HCC, liver cancer, imaging tools, biomarkers, TACE, targeted therapy, multidisciplinary management PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the rationale for studying maintenance therapy in NSCLC settings and the clinical implications of new data on the maintenance use of active cytotoxic agents and targeted therapy in patients with advanced NSCLC. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE05904r67.mp3 Fri, 25 Sep 2009 14:51:18 -0400 Science, Medicine no 00:14:52 maintenance, NSCLC, lung cancer, cytotoxic, JMEN, Fidias, nonsquamous, squamous, histology, erlotinib, advanced PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05904CMEinfo.pdf Fri, 25 Sep 2009 14:51:15 -0400 Science, Medicine no 00:00:00 maintenance, NSCLC, lung cancer, cytotoxic, JMEN, Fidias, nonsquamous, squamous, histology, erlotinib, advanced PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts provide recommendations for management of disease- and treatment-related complications in multiple myeloma. In the 3 presentations, issues related to thrombosis, neuropathy, and myeloma bone disease are discussed. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA04348FCr66.mp3 Mon, 21 Sep 2009 15:16:50 -0400 Science, Medicine no 00:27:28 peripheral neuropathy, bortezomib, multiple myeloma, DVT, bone disease, vincristine, VTE, LMWH PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA04348FCCMEinfo.pdf Mon, 21 Sep 2009 15:16:47 -0400 Science, Medicine no 00:00:00 peripheral neuropathy, bortezomib, multiple myeloma, DVT, bone disease, vincristine, VTE, LMWH PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest clinical trial data on the use of maintenance therapy, the clinical role of biomarkers in selecting the most appropriate therapy, and the potential of novel agents and combination strategies for advanced lung cancer. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05722FCs143.mp3 Tue, 08 Sep 2009 15:09:27 -0400 Science, Medicine no 00:34:29 NSCLC, lung cancer, histology, PFS, pemetrexed, nonsquamous, squamous, EGFR, JMEN, SATURN, Fidias PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05722FCCMEinfo.pdf Tue, 08 Sep 2009 15:09:26 -0400 Science, Medicine no 00:00:00 NSCLC, lung cancer, histology, PFS, pemetrexed, nonsquamous, squamous, EGFR, JMEN, SATURN, Fidias PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in CML management discuss the nature of higher risk CML and the current controversies over the criteria that define accelerated-phase and blast-crisis disease. In addition, the faculty will review the currently recommended treatment options for these patient populations and discuss the changed role of tyrosine kinase inhibitor (TKI) therapy in this more advanced setting. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05790FCe24.mp3 Mon, 17 Aug 2009 13:42:34 -0400 Science, Medicine no 00:26:18 chronic myeloid leukemia, CML, TKI, targeted therapy, blast, chronic, accelerated, phase, imatinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05790FCCMEinfo.pdf Mon, 17 Aug 2009 13:42:32 -0400 Science, Medicine no 00:00:00 chronic myeloid leukemia, CML, TKI, targeted therapy, blast, chronic, accelerated, phase, imatinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert discusses the latest clinical trial data on targeted therapies for upfront treatment of metastatic RCC, assesses the clinical implications of these data, and provides recommendations for optimal integration of new agents into the current treatment paradigm for advanced RCC. http://podcast.peerviewpress.com/oncology/PPVNE05963s142.mp3 http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE05963s142.mp3 Wed, 12 Aug 2009 15:34:59 -0400 Science, Medicine no 00:15:31 renal cell carcinoma, RCC, bevacizumab, sunitinib, sorafenib, interferon, VEGF, TKI, pazopanib, ASCO PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05963CMEinfo.pdf Wed, 12 Aug 2009 15:34:56 -0400 Science, Medicine no 00:00:00 renal cell carcinoma, RCC, bevacizumab, sunitinib, sorafenib, interferon, VEGF, TKI, pazopanib, ASCO PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this educational activity, 3 clinical experts in NSCLC discuss the current state and potential future directions of targeted therapy for the treatment of this disease in its advanced stages. Highlights of this discussion include the integration of these therapies into first-line treatment and maintenance regimens for advanced NSCLC, emerging molecular targeted agents for recurrent/refractory disease, and the application of predictive and prognostic markers as well as other patient-specific and disease-related characteristics for treatment selection in patients with this malignancy. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05538FCe20.mp3 Tue, 11 Aug 2009 15:26:34 -0400 Science, Medicine no 00:34:43 non small cell lung cancer, NSCLC, gemcitabine, bevacizumab, cisplatin, pemetrexed, FLEX, erlotinib PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05538FCCMEinfo.pdf Tue, 11 Aug 2009 15:26:31 -0400 Science, Medicine no 00:00:00 non small cell lung cancer, NSCLC, gemcitabine, bevacizumab, cisplatin, pemetrexed, FLEX, erlotinib PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, a panel of experts evaluates the latest data on new targeted and cytotoxic treatment options for ovarian cancer (OC), and debates key issues, controversies, and challenges related to management of patients with OC. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE05890e030.mp3 Tue, 04 Aug 2009 14:19:01 -0400 Science, Medicine no 00:25:09 ovarian, gynecologic cancer, bevacizumab, antiangiogenesis, CA-125, BRCA, bowel perforation, PLD, platinum resistance PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05890CMEinfo.pdf Tue, 04 Aug 2009 14:18:58 -0400 Science, Medicine no 00:00:00 ovarian, gynecologic cancer, bevacizumab, antiangiogenesis, CA-125, BRCA, bowel perforation, PLD, platinum resistance PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest clinical trial data on targeted and other new therapies for glioblastoma multiforme, assess the clinical implications of these data, and review some of the key ongoing studies that clinicians and patients should be aware of. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PPVNE05931s554.mp3 Fri, 24 Jul 2009 14:45:54 -0400 Science, Medicine no 00:17:37 glioblastoma multiforme, GBM, bevacizumab, temozolomide, radiation, VEGF inhibitor, mTOR, irinotecan, antiangiogenic, immunostimulation PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PPVNE05931CMEinfo.pdf Fri, 24 Jul 2009 14:45:35 -0400 Science, Medicine no 00:00:00 glioblastoma multiforme, GBM, bevacizumab, temozolomide, radiation, VEGF inhibitor, mTOR, irinotecan, antiangiogenic, immunostimulation PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in CLL management discusses the elements of high-risk CLL and the appropriate assessment of poor-prognosis features leading to optimal therapy selection in both the upfront and relapsed/refractory setting. Treatment decisions in unsymptomatic and progressive disease will be explored, and the management of elderly individuals will also be considered. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05757FCp155.mp3 Thu, 16 Jul 2009 16:08:03 -0400 Science, Medicine no 00:23:46 high-risk, chronic lymphocytic leukemia, CLL, elderly, relapsed, refractory, upfront, alemtuzumab, fludarabine PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05757FCCMEinfo.pdf Thu, 16 Jul 2009 16:08:00 -0400 Science, Medicine no 00:00:00 high-risk, chronic lymphocytic leukemia, CLL, elderly, relapsed, refractory, upfront, alemtuzumab, fludarabine PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in oncology discuss the latest data on current and emerging therapies for advanced renal cell carcinoma. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05679FCs545.mp3 Wed, 15 Jul 2009 16:01:29 -0400 Science, Medicine no 00:23:35 renal cell carinoma, RCC, AVOREN, CALGB, bevacizumab, interferon, TKI, pazopanib, sunitinib, AV-951 PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05679FCCMEinfo.pdf Wed, 15 Jul 2009 16:01:23 -0400 Science, Medicine no 00:00:00 renal cell carinoma, RCC, AVOREN, CALGB, bevacizumab, interferon, TKI, pazopanib, sunitinib, AV-951 PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in colorectal cancer (CRC) discusses the clinical implications of new and breaking data on the role of targeted agents as adjuvant therapy in early-stage CRC and the potential development of prognostic and predictive factors. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05724FCs553.mp3 Thu, 09 Jul 2009 15:28:42 -0400 Science, Medicine no 00:13:36 colorectal cancer, early-stage CRC, targeted, antiangiogenic therapy, bevacizumab, FOLFOX, biomarkers, high microsatellite instability, oxaliplatin, oral fluoropyrimidines PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05724FCCMEinfo.pdf Thu, 09 Jul 2009 15:28:37 -0400 Science, Medicine no 00:00:00 colorectal cancer, early-stage CRC, targeted, antiangiogenic therapy, bevacizumab, FOLFOX, biomarkers, high microsatellite instability, oxaliplatin, oral fluoropyrimidines PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in breast cancer discusses how to approach the management of a patient with metastatic HER2-positive breast cancer throughout the disease course. This program follows a patient scenario to help improve oncologists' understanding of the current standards of care and increase their awareness of emerging clinical trends in HER2-positive advanced breast cancer. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA04959FCr450.mp3 Wed, 08 Jul 2009 14:27:44 -0400 Science, Medicine no 00:22:03 HER2, metastatic breast cancer, IHC, FISH, Oncotype, HERmark, endocrine therapy PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA4959FCCMEinfo.pdf Wed, 08 Jul 2009 14:27:41 -0400 Science, Medicine no 00:00:00 HER2, metastatic breast cancer, IHC, FISH, Oncotype, HERmark, endocrine therapy PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss the latest advances in the treatment of multiple myeloma, with a focus on appropriate and clinically relevant endpoints for assessing the benefit of new therapies, and results of recent clinical trials to determine if these newer agents have convincingly demonstrated improvements in efficacy. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05541FCr440.mp3 Thu, 02 Jul 2009 16:19:13 -0400 Science, Medicine no 00:23:51 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05541FCCMEinfo.pdf Thu, 02 Jul 2009 16:19:10 -0400 Science, Medicine no 00:00:00 multiple myeloma, endpoints, bortezomib, cytogenetics, VAD, ASCT, dexamethasone, lenalidomide. ASH, ASCO PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. This 2-part activity focuses on some of the practical aspects of chronic pain management. Highlights from the first part of the activity include the various definitions, types, and characteristics of chronic pain. Considerations for the management of special populations with chronic pain are also discussed. The second part of the activity emphasizes the importance of patient communication, summarizes therapeutic modalities, details the rationale and challenges associated with the interdisciplinary management of chronic pain, and provides strategies for physicians when this approach is not feasible. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05601FCe028.mp3 Thu, 25 Jun 2009 15:22:29 -0400 Science, Medicine no 00:23:32 chronic pain, pain, pain management, neuropathy PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05601FCCMEinfo.pdf Thu, 25 Jun 2009 15:22:25 -0400 Science, Medicine no 00:00:00 chronic pain, pain, pain management, neuropathy PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in multiple myeloma bone health management discuss the development and clinical impact of myeloma bone disease and the identification of several promising therapeutic targets within the bone microenvironment. Several other topics will be addressed, including the current recommendations for bone disease assessment and management, as well as the potential role of novel therapies with bone protective aspects. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05569FCr447.mp3 Fri, 22 May 2009 15:48:00 -0400 Science, Medicine no 00:24:11 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05569FCCMEinfo.pdf Fri, 22 May 2009 15:47:57 -0400 Science, Medicine no 00:00:00 multiple myeloma bone disease, MBD, bisphosphonates, zoledronic acid, RANK Ligand, ACE, activin PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in MCL discusses the characteristics of this relatively rare and clinically challenging disease, including its natural course and typical unresponsiveness to most front-line treatment options. The nature of resistant disease will also be profiled, and the activity of a novel generation of therapeutics in previously treated patients will be evaluated. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05230FCn208.mp3 Wed, 13 May 2009 10:17:58 -0400 Science, Medicine no 00:18:52 mantle cell lymphoma, MCL, CVAD, rituximab, everolimus, mTOR, PINNACLE, bortezomib, temsirolimus, ASH PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05230FCCMEinfo.pdf Wed, 13 May 2009 10:17:56 -0400 Science, Medicine no 00:00:00 mantle cell lymphoma, MCL, CVAD, rituximab, everolimus, mTOR, PINNACLE, bortezomib, temsirolimus, ASH PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts discuss recent advances in the management of kidney cancer. Latest data on new and emerging targeted treatment options will be evaluated, treatment options for RCC with sarcomatoid features will be discussed, and an evidence-based treatment algorithm for optimal integration of targeted agents into the current treatment paradigm will be provided. Additionally, research findings from studies aiming to refine the treatment of RCC will be highlighted, including those assessing the potential role of new prognostic models, clinical and genotypic variations that might influence or predict the development of toxicities associated with targeted therapies, and strategies for prevention or overcoming treatment resistance. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05349FCs515.mp3 Mon, 11 May 2009 14:41:39 -0400 Science, Medicine no 00:20:24 renal carcinoma, RCC, bevacizumab, everolimus, sorafenib, sunitnib, TKI, AV-951, VEGF, prognostic models PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05349FCCMEinfo.pdf Mon, 11 May 2009 14:41:37 -0400 Science, Medicine no 00:00:00 renal carcinoma, RCC, bevacizumab, everolimus, sorafenib, sunitnib, TKI, AV-951, VEGF, prognostic models PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in the management of adults with hemophilia and inhibitors discuss the diagnosis and treatment of allo- and autoantibodies, as well as future directions for managing patients with hemophilia and inhibitors. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05327FCe027.mp3 Thu, 30 Apr 2009 14:24:33 -0400 Science, Medicine no 00:54:23 hemophilia, hemophilia inhibitors, hemophilia treatment, alloantibodies, autoantibodies PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05327FCCMEinfo.pdf Thu, 30 Apr 2009 14:24:29 -0400 Science, Medicine no 00:00:00 hemophilia, hemophilia inhibitors, hemophilia treatment, alloantibodies, autoantibodies PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in CRC management discusses contrasting approaches to treating elderly individuals presenting with advanced disease. Two case scenarios will illustrate how therapeutic decision-making may be influenced by patient health and performance status or a patients? willingness to pursue aggressive treatment. In addition, the clinical consequences of specific comorbidities or tumor-related factors will also be explored. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05540FCp153.mp3 Wed, 29 Apr 2009 16:14:28 -0400 Science, Medicine no 00:21:40 metastatic CRC, FOLFOX, FOLFIRI, elderly, performance status, CapeOX, bevacizumab, 5-FU, panitumumab, KRAS PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05540FCCMEinfo.pdf Wed, 29 Apr 2009 16:14:26 -0400 Science, Medicine no 00:00:00 metastatic CRC, FOLFOX, FOLFIRI, elderly, performance status, CapeOX, bevacizumab, 5-FU, panitumumab, KRAS PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert in iron overload discusses the differences between hereditary and transfusional hemochromatosis, and evaluates the role of iron chelation in the management of the latter, including both single-agent and combination approaches. New data on the ability of chelators to reduce cardiac iron burden in patients with transfusional iron overload are also discussed. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05130FCn202.mp3 Wed, 22 Apr 2009 11:38:43 -0400 Science, Medicine no 00:23:04 hemochramatosis, chelator, iron overload, MDS, transfusion, transferrin, thalassemia, deferiprone, deferoxamine PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05130FCCMEinfo.pdf Wed, 22 Apr 2009 11:38:40 -0400 Science, Medicine no 00:00:00 hemochramatosis, chelator, iron overload, MDS, transfusion, transferrin, thalassemia, deferiprone, deferoxamine PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in breast cancer discuss current evidence on the risk of cardiotoxicity associated with various breast cancer therapies and provide practical recommendations for preventing, monitoring and managing cardiovascular adverse effects in patients undergoing treatment for breast cancer. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05378FCr430.mp3 Mon, 06 Apr 2009 15:02:01 -0400 Science, Medicine no 00:20:45 breast cancer, cardiotoxicity, trastuzumab, HERA, CHF, hypertension, cardiac events, LVEF, anthracyclines PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05378FCCMEinfo.pdf Mon, 06 Apr 2009 15:01:59 -0400 Science, Medicine no 00:00:00 breast cancer, cardiotoxicity, trastuzumab, HERA, CHF, hypertension, cardiac events, LVEF, anthracyclines PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts on breast cancer provide a concise summary of the latest and most clinically relevant data on endocrine therapies for breast cancer, and discuss how to integrate this information into everyday patient care. http://media.peerviewpress.com/000136/podcast/pvi/mp3/PA05150FCs512.mp3 Thu, 02 Apr 2009 14:50:48 -0400 Science, Medicine no 00:34:47 breast cancer, endocrine therapy, aromatase inhibitors, tamoxifen, SABCS, bone loss, predictive markers PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://media.peerviewpress.com/000136/podcast/pvi/pdf/PA05150FCCMEinfo.pdf Thu, 02 Apr 2009 14:50:45 -0400 Science, Medicine no 00:00:00 breast cancer, endocrine therapy, aromatase inhibitors, tamoxifen, SABCS, bone loss, predictive markers